

# Keith L Knutson

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2362076/publications.pdf>

Version: 2024-02-01

91  
papers

13,352  
citations

57631

44  
h-index

45213

90  
g-index

93  
all docs

93  
docs citations

93  
times ranked

16972  
citing authors

#	ARTICLE	IF	CITATIONS
1	Humoral Responses After SARS-CoV-2 mRNA Vaccination and Breakthrough Infection in Cancer Patients. <i>Mayo Clinic Proceedings Innovations, Quality &amp; Outcomes</i> , 2022, 6, 120-125.	1.2	10
2	Adaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trials. <i>Npj Breast Cancer</i> , 2022, 8, .	2.3	4
3	A pilot trial of intravital microscopy in the study of the tumor vasculature of patients with peritoneal carcinomatosis. <i>Scientific Reports</i> , 2021, 11, 4946.	1.6	5
4	Cytotoxic T cell depletion with increasing epithelial abnormality in women with benign breast disease. <i>Breast Cancer Research and Treatment</i> , 2020, 180, 55-61.	1.1	4
5	Longitudinal relationships between rheumatoid factor and cytokine expression by immunostimulated peripheral blood lymphocytes from patients with rheumatoid arthritis: New insights into B-cell activation. <i>Clinical Immunology</i> , 2020, 211, 108342.	1.4	6
6	Th17-inducing autologous dendritic cell vaccination promotes antigen-specific cellular and humoral immunity in ovarian cancer patients. <i>Nature Communications</i> , 2020, 11, 5173.	5.8	46
7	Dynamic control of tumor vasculature improves antitumor responses in a regional model of melanoma. <i>Scientific Reports</i> , 2020, 10, 13245.	1.6	6
8	Immune Responses and Risk of Triple-negative Breast Cancer: Implications for Higher Rates among African American Women. <i>Cancer Prevention Research</i> , 2020, 13, 901-910.	0.7	10
9	Targeting CD38 is lethal to Breg-like chronic lymphocytic leukemia cells and Tregs, but restores CD8+ T-cell responses. <i>Blood Advances</i> , 2020, 4, 2143-2157.	2.5	27
10	Safety, immunogenicity, and clinical efficacy of durvalumab in combination with folate receptor alpha vaccine TPIV200 in patients with advanced ovarian cancer: a phase II trial. , 2020, 8, e000829.		34
11	Folate receptor alpha expression associates with improved disease-free survival in triple negative breast cancer patients. <i>Npj Breast Cancer</i> , 2020, 6, 4.	2.3	49
12	Rapid Generation of Sustainable HER2-specific T-cell Immunity in Patients with HER2 Breast Cancer using a Degenerate HLA Class II Epitope Vaccine. <i>Clinical Cancer Research</i> , 2020, 26, 1045-1053.	3.2	13
13	HLA class-I and class-II restricted neoantigen loads predict overall survival in breast cancer. <i>OncImmunity</i> , 2020, 9, 1744947.	2.1	26
14	Hypereosinophilia in a patient with metastatic non-small-cell lung cancer treated with antiprogrammed cell death 1 (anti-PD-1) therapy. <i>Immunotherapy</i> , 2019, 11, 577-584.	1.0	18
15	Effects of Age and Immune Landscape on Outcome in HER2-Positive Breast Cancer in the NCCTG N9831 (Alliance) and NSABP B-31 (NRG) Trials. <i>Clinical Cancer Research</i> , 2019, 25, 4422-4430.	3.2	6
16	Cancer immunotherapy beyond immune checkpoint inhibitors. <i>Journal of Hematology and Oncology</i> , 2018, 11, 8.	6.9	174
17	Next generation of immune checkpoint therapy in cancer: new developments and challenges. <i>Journal of Hematology and Oncology</i> , 2018, 11, 39.	6.9	597
18	Folate Receptor Alpha Peptide Vaccine Generates Immunity in Breast and Ovarian Cancer Patients. <i>Clinical Cancer Research</i> , 2018, 24, 3014-3025.	3.2	64

#	ARTICLE	IF	CITATIONS
19	Macrophagic "Crown-like Structures" Are Associated with an Increased Risk of Breast Cancer in Benign Breast Disease. <i>Cancer Prevention Research</i> , 2018, 11, 113-119.	0.7	50
20	Immune checkpoint inhibition by anti-PD-1 (anti-PD-1) monoclonal antibody has significant therapeutic activity against central nervous system lymphoma in an immunocompetent preclinical model. <i>British Journal of Haematology</i> , 2018, 183, 674-678.	1.2	22
21	Generation of HER2-specific antibody immunity during trastuzumab adjuvant therapy associates with reduced relapse in resected HER2 breast cancer. <i>Breast Cancer Research</i> , 2018, 20, 52.	2.2	12
22	Alterations in the Immune Cell Composition in Premalignant Breast Tissue that Precede Breast Cancer Development. <i>Clinical Cancer Research</i> , 2017, 23, 3945-3952.	3.2	46
23	Multivalent bi-specific nanobioconjugate engager for targeted cancer immunotherapy. <i>Nature Nanotechnology</i> , 2017, 12, 763-769.	15.6	136
24	IL10 Release upon PD-1 Blockade Sustains Immunosuppression in Ovarian Cancer. <i>Cancer Research</i> , 2017, 77, 6667-6678.	0.4	126
25	The Association of Peripheral Blood Regulatory T-Cell Concentrations With Epithelial Ovarian Cancer: A Brief Report. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 11-16.	1.2	9
26	Cytokine and neuropeptide levels are associated with pain relief in patients with chronically painful total knee arthroplasty: a pilot study. <i>BMC Musculoskeletal Disorders</i> , 2017, 18, 17.	0.8	18
27	Downregulation of TAP1 and TAP2 in early stage breast cancer. <i>PLoS ONE</i> , 2017, 12, e0187323.	1.1	38
28	Improved Survival of HER2+ Breast Cancer Patients Treated with Trastuzumab and Chemotherapy Is Associated with Host Antibody Immunity against the HER2 Intracellular Domain. <i>Cancer Research</i> , 2016, 76, 3702-3710.	0.4	51
29	The Microbiome of Aseptically Collected Human Breast Tissue in Benign and Malignant Disease. <i>Scientific Reports</i> , 2016, 6, 30751.	1.6	299
30	PD-1 Blunts the Function of Ovarian Tumor-Infiltrating Dendritic Cells by Inactivating NF- $\kappa$ B. <i>Cancer Research</i> , 2016, 76, 239-250.	0.4	84
31	Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer. <i>Oncotarget</i> , 2016, 7, 69097-69110.	0.8	5
32	Plasma immune analytes in patients with epithelial ovarian cancer. <i>Cytokine</i> , 2015, 73, 108-113.	1.4	31
33	Tumor-Infiltrating Dendritic Cells in Cancer Pathogenesis. <i>Journal of Immunology</i> , 2015, 194, 2985-2991.	0.4	369
34	Cancer vaccines in the new era of cancer immunotherapy. <i>Vaccine</i> , 2015, 33, 7376.	1.7	7
35	Regulatory T cells, inherited variation, and clinical outcome in epithelial ovarian cancer. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 1495-1504.	2.0	51
36	Oncolytic Measles Virus Expressing the Sodium Iodide Symporter to Treat Drug-Resistant Ovarian Cancer. <i>Cancer Research</i> , 2015, 75, 22-30.	0.4	157

#	ARTICLE	IF	CITATIONS
37	Tumor Hypomethylation at 6p21.3 Associates with Longer Time to Recurrence of High-Grade Serous Epithelial Ovarian Cancer. <i>Cancer Research</i> , 2014, 74, 3084-3091.	0.4	32
38	Large-Scale Evaluation of Common Variation in Regulatory T Cell-Related Genes and Ovarian Cancer Outcome. <i>Cancer Immunology Research</i> , 2014, 2, 332-340.	1.6	21
39	Accumulation of Memory Precursor CD8 T Cells in Regressing Tumors following Combination Therapy with Vaccine and Anti-PD-1 Antibody. <i>Cancer Research</i> , 2014, 74, 2974-2985.	0.4	136
40	Association Studies of Fcγ3 Receptor Polymorphisms with Outcome in HER2+ Breast Cancer Patients Treated with Trastuzumab in NCCTG (Alliance) Trial N9831. <i>Cancer Immunology Research</i> , 2014, 2, 962-969.	1.6	44
41	The Ratios of CD8+ T Cells to CD4+CD25+ FOXP3+ and FOXP3- T Cells Correlate with Poor Clinical Outcome in Human Serous Ovarian Cancer. <i>PLoS ONE</i> , 2013, 8, e80063.	1.1	171
42	Inherited Variants in Regulatory T Cell Genes and Outcome of Ovarian Cancer. <i>PLoS ONE</i> , 2013, 8, e53903.	1.1	20
43	The Immune System in the Pathogenesis of Ovarian Cancer. <i>Critical Reviews in Immunology</i> , 2013, 33, 137-164.	1.0	55
44	The Immune System in Breast Cancer Initiation and Progression: Role of Epithelial to Mesenchymal Transition. , 2013, , 43-64.		0
45	Immunity and immune suppression in human ovarian cancer. <i>Immunotherapy</i> , 2011, 3, 539-556.	1.0	102
46	MHC Class II Epitope Nesting Modulates Dendritic Cell Function and Improves Generation of Antigen-Specific CD4 Helper T Cells. <i>Journal of Immunology</i> , 2011, 187, 316-324.	0.4	15
47	Tumor-Infiltrating Programmed Death Receptor-1+ Dendritic Cells Mediate Immune Suppression in Ovarian Cancer. <i>Journal of Immunology</i> , 2011, 186, 6905-6913.	0.4	209
48	Identification of a broad coverage HLA-DR degenerate epitope pool derived from carcinoembryonic antigen. <i>Cancer Immunology, Immunotherapy</i> , 2010, 59, 161-171.	2.0	12
49	A Degenerate HLA-DR Epitope Pool of HER-2/neu Reveals a Novel In vivo Immunodominant Epitope, HER-2/neu88-102. <i>Clinical Cancer Research</i> , 2010, 16, 825-834.	3.2	15
50	Immune Promotion of Epithelial-mesenchymal Transition and Generation of Breast Cancer Stem Cells. <i>Cancer Research</i> , 2010, 70, 3005-3008.	0.4	99
51	Antibodies in cancer immunotherapy. <i>Cancer Biomarkers</i> , 2010, 6, 291-305.	0.8	2
52	Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial. <i>Journal of Translational Medicine</i> , 2010, 8, 53.	1.8	104
53	Functional Folate Receptor Alpha Is Elevated in the Blood of Ovarian Cancer Patients. <i>PLoS ONE</i> , 2009, 4, e6292.	1.1	64
54	Immune-Induced Epithelial to Mesenchymal Transition <i>In vivo</i> Generates Breast Cancer Stem Cells. <i>Cancer Research</i> , 2009, 69, 2887-2895.	0.4	369

#	ARTICLE	IF	CITATIONS
55	Intraepithelial Effector (CD3+)/Regulatory (FoxP3+) T-Cell Ratio Predicts a Clinical Outcome of Human Colon Carcinoma. <i>Gastroenterology</i> , 2009, 137, 1270-1279.	0.6	273
56	Folate receptor alpha as a tumor target in epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2008, 108, 619-626.	0.6	365
57	The endogenous danger signal, crystalline uric acid, signals for enhanced antibody immunity. <i>Blood</i> , 2008, 111, 1472-1479.	0.6	71
58	An HLA-DR $\alpha$ -Specific Degenerate Epitope Pool Detects Insulin-like Growth Factor Binding Protein 2-Specific Immunity in Patients with Cancer. <i>Cancer Research</i> , 2008, 68, 4893-4901.	0.4	16
59	Therapeutic vaccines for malignant brain tumors. <i>Biologics: Targets and Therapy</i> , 2008, 2, 753.	3.0	8
60	Tumor-Infiltrating Foxp3 $^{hi}$ CD4 $^{hi}$ CD25 $^{hi}$ T Cells Predict Poor Survival in Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2007, 13, 2075-2081.	3.2	188
61	Tumor Antigen-Specific T-Cell Expansion Is Greatly Facilitated by In vivo Priming. <i>Clinical Cancer Research</i> , 2007, 13, 1883-1891.	3.2	34
62	Augmented HER-2-Specific Immunity during Treatment with Trastuzumab and Chemotherapy. <i>Clinical Cancer Research</i> , 2007, 13, 5133-5143.	3.2	194
63	Peptide Vaccine Given with a Toll-Like Receptor Agonist Is Effective for the Treatment and Prevention of Spontaneous Breast Tumors. <i>Cancer Research</i> , 2007, 67, 1326-1334.	0.4	97
64	HER-2/neu antigen loss and relapse of mammary carcinoma are actively induced by T cell-mediated anti-tumor immune responses. <i>European Journal of Immunology</i> , 2007, 37, 675-685.	1.6	92
65	Tumor immunoediting and immunosculpting pathways to cancer progression. <i>Seminars in Cancer Biology</i> , 2007, 17, 275-287.	4.3	167
66	Laboratory Analysis of T-Cell Immunity. <i>Frontiers in Bioscience - Landmark</i> , 2006, 11, 1932.	3.0	21
67	Emergence of immune escape variant of mammary tumors that has distinct proteomic profile and a reduced ability to induce $\alpha$ -danger signals. <i>Breast Cancer Research and Treatment</i> , 2006, 96, 233-241.	1.1	20
68	Adoptive T cell therapy of solid cancers. <i>Cancer Immunology, Immunotherapy</i> , 2006, 55, 96-103.	2.0	28
69	CD4 regulatory T cells in human cancer pathogenesis. <i>Cancer Immunology, Immunotherapy</i> , 2006, 56, 271-285.	2.0	100
70	Strong-arming immune regulation: suppressing regulatory T-cell function to treat cancers. <i>Future Oncology</i> , 2006, 2, 379-389.	1.1	6
71	The Tumor Antigen Repertoire Identified in Tumor-Bearing Neu Transgenic Mice Predicts Human Tumor Antigens. <i>Cancer Research</i> , 2006, 66, 9754-9761.	0.4	50
72	Immunoediting of Cancers May Lead to Epithelial to Mesenchymal Transition. <i>Journal of Immunology</i> , 2006, 177, 1526-1533.	0.4	116

#	ARTICLE	IF	CITATIONS
73	IL-2 Immunotoxin Therapy Modulates Tumor-Associated Regulatory T Cells and Leads to Lasting Immune-Mediated Rejection of Breast Cancers in <i>neu</i> -Transgenic Mice. <i>Journal of Immunology</i> , 2006, 177, 84-91.	0.4	118
74	T-Cell Immunity to the Folate Receptor Alpha Is Prevalent in Women With Breast or Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2006, 24, 4254-4261.	0.8	68
75	Cancer vaccines: The next generation. <i>Drug Discovery Today: Therapeutic Strategies</i> , 2005, 2, 323-330.	0.5	2
76	<i>neu</i> Antigen-Negative Variants Can Be Generated after <i>neu</i> -Specific Antibody Therapy in <i>neu</i> Transgenic Mice. <i>Cancer Research</i> , 2004, 64, 1146-1151.	0.4	63
77	Effect of Dose on Immune Response in Patients Vaccinated With an HER-2/ <i>neu</i> Intracellular Domain Protein-Based Vaccine. <i>Journal of Clinical Oncology</i> , 2004, 22, 1916-1925.	0.8	149
78	Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. <i>Nature Medicine</i> , 2004, 10, 942-949.	15.2	4,442
79	Humoral Epitope-Spreading Following Immunization with a HER-2/ <i>neu</i> Peptide Based Vaccine in Cancer Patients. <i>Journal of Clinical Immunology</i> , 2004, 24, 571-578.	2.0	104
80	Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. <i>Nature Medicine</i> , 2003, 9, 562-567.	15.2	1,157
81	Soluble Cytokines Can Act as Effective Adjuvants in Plasmid DNA Vaccines Targeting Self Tumor Antigens. <i>Immunobiology</i> , 2003, 207, 179-186.	0.8	24
82	Immunization of cancer patients with HER-2/ <i>neu</i> -derived peptides demonstrating high-affinity binding to multiple class II alleles. <i>Clinical Cancer Research</i> , 2003, 9, 5559-65.	3.2	62
83	Generation of T-Cell Immunity to the HER-2/ <i>neu</i> Protein After Active Immunization With HER-2/ <i>neu</i> Peptide-Based Vaccines. <i>Journal of Clinical Oncology</i> , 2002, 20, 2624-2632.	0.8	411
84	Adoptive T-cell therapy for the treatment of solid tumours. <i>Expert Opinion on Biological Therapy</i> , 2002, 2, 55-66.	1.4	16
85	Clonal diversity of the T-cell population responding to a dominant HLA-A2 epitope of HER-2/ <i>neu</i> after active immunization in an ovarian cancer patient. <i>Human Immunology</i> , 2002, 63, 547-557.	1.2	18
86	Immunization of cancer patients with a HER-2/ <i>neu</i> , HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity. <i>Clinical Cancer Research</i> , 2002, 8, 1014-8.	3.2	210
87	Immunotherapy for breast cancer. <i>Cancer Chemotherapy and Biological Response Modifiers</i> , 2002, 20, 351-69.	0.5	4
88	Expansion of HER2/ <i>neu</i> -Specific T Cells Ex Vivo Following Immunization with a HER2/ <i>neu</i> Peptide-Based Vaccine. <i>Clinical Breast Cancer</i> , 2001, 2, 73-79.	1.1	28
89	Immunization with a HER-2/ <i>neu</i> helper peptide vaccine generates HER-2/ <i>neu</i> CD8 T-cell immunity in cancer patients. <i>Journal of Clinical Investigation</i> , 2001, 107, 477-484.	3.9	368
90	Pre-existent immunity to the HER-2/ <i>neu</i> oncogenic protein in patients with HER-2/ <i>neu</i> overexpressing breast and ovarian cancer. <i>Breast Cancer Research and Treatment</i> , 2000, 62, 245-252.	1.1	139

#	ARTICLE	IF	CITATIONS
91	Immunotherapeutic approaches for the treatment of breast cancer. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 1999, 4, 353-365.	1.0	19